A decade to next year

Last May, NewLimit told its investors that a clinic-ready medicine to slow aging was more than a decade off. This month it told a new set of investors the first human trial would start next year, and they valued the company at $3.1 billion — roughly three times what it was worth twelve months ago. Founders Fund led the round; Eli Lilly's venture arm came back in, the same drugmaker that has been buying its way into longevity and heart medicine elsewhere.

Last May NewLimit told investors a clinic-ready drug was a decade off; this month, a decade became next year — and Founders Fund and Eli Lilly's venture arm valued that reversal at $3.1B on faith.

What collapsed the timeline, the company says, is a single prototype that reverses the age of old human liver cells in the lab. That is the whole bet — and it is also the part you cannot check. NewLimit has published no paper, no preprint, no numbers, and has not said which molecular switches it is flipping. No outlet that covered the raise found an outside scientist willing to vouch for or pick apart the result.

The biology underneath is not new: nudging old cells back toward a younger state with a partial dose of reprogramming factors is decade-old academic work, and richer rivals — Altos, Retro, David Sinclair's Life Biosciences — have been at it for years. Life Biosciences holds the actual lead, the first human trial of this approach, run narrowly in the eye because containing the cells limits the cancer risk. NewLimit's claim to the frontier is going after a large internal organ instead, and going fast. The number that matters here isn't the valuation. It's the distance between a result no one outside the company has seen and a price that says it already worked.